Publication

Abstract : The clinical use of gemcitabine (GEM), a frontline chemotherapeutic agent for pancreatic ductal adenocarcinoma (PDAC), is limited by its short half-life, rapid systemic clearance, associated dose-limiting toxicities and a faster development of resistance in pancreatic cancer. Aspirin (ASP), a repurposed NSAID, has been shown to sensitize PDAC cells to GEM through modulation of multiple oncogenic and inflammatory pathways. However, its clinical use is restricted by dose-dependent gastrointestinal toxicity. To overcome these challenges, we present a bulk and surface engineered oral ASP delivery system (ASNC-1& ASNC-2) that leverages “controlled polymorphism” inside drug reservoir to achieve sustained release followed by increase in bioavailability for prolonged duration with enhanced gastric safety. Two novel oral formulations, ASNC-1 and ASNC-2 were developed through a bulk and surface engineering strategy. ASNC-1 employed polymorphic control within an ethyl cellulose-based reservoir to stabilize the polymorphic forms of ASP for enhanced solubility and prolonged release. ASNC-2 integrated a PEG-PPG-PEG copolymer with a lipid layers to enhance mucosal protection and systemic absorption. Co-administration of ASNC-2 with low-dose GEM (¼ standard dose) demonstrated superior antitumor efficacy with reduced toxicity in a DMBA-induced PDAC rat model. This formulation enabled effective chemopotentiation while minimizing GEM-associated side effects, offering a clinically translatable, gastroprotective strategy for oral adjuvant therapy. The study exemplifies how the control of polymorphic form, release kinetics, and surface engineering can overcome key limitations of combination chemotherapy. These findings highlight a novel NSAID based delivery platform with potential to improve outcomes in pancreatic cancer therapy through a rational, mechanism-driven sustained release approach.